SOPHiA GENETICS
Oncology
-
On-demandLymphoid neoplasms encompassing lymphomas and some leukemia like Chronic Lymphocytic Leukaemia (CLL) are the most common type of blood cancer .
With increasing evidence for the stratification of tumor types with distinct clinical and biological fe... -
On-demandThis talk was presented at CGC 2021 on August 2nd, 2021. Join our experts to learn more about how the SOPHiA DDM™ platform supports solid tumor detection.
Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS ... -
On-demandThis webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.
Molecular profiling by next... -
On-demandThis webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources.
The evolution of molecular oncolog... -
On-demandCombining Genomics and Radiomics Data in Oncology: examples for lung and breast tumors.
Thierry Colin, VP Radiomics, SOPHiA GENETICS
Radiomics and Artificial Intelligence: what may the future bring
Prof. Dimitris Visvikis, Dimitris Visvikis, INSE... -
On-demandLearn how SOPHiA GENETICS can support you in overcoming the limitations and maximizing the ability to detect Homologous Recombination Repair (HRR) deficiency in somatic samples.
Following an introduction on the growing importance of broadening HR... -
On-demandPart 1: Homologous Recombination Deficiency (HRD) Detection
Originally presented at ESMO 2022
What’s New? CE-IVD Oncology Applications by SOPHiA GENETICS
Alexander Kurze, PhD
Evaluation of a low-pass whole genome sequencing-based solution for... -
On-demandPart 2: RNA fusion detection
Originally presented at ESMO 2022
Clinical validation of novel RNA fusion detection for NSCLC with SOPHiA DDM™ Dx RNAtarget Oncology Solution
Prof. Alexander Harlé, PhD
Enabling clinical workflows in Trusted Resea... -
On-demandPresented at The Cancer Genomics Consortium 2022 Annual Meeting.
Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker... -
Friday, July 22, 2022 · 2:00 PM CESTDeficiency in the homologous recombination repair system represents up to 50% of ovarian, breast, prostate, and pancreatic cancers. While Poly ADP-ribose polymerase inhibitors (PARPi) treatment revolutionized the management of patients, inducing s...
-
Thursday, June 30, 2022 · 4:00 PM CESTGene fusions are the latest type of biomarker to receive broad applicability in cancer management. More than 10,000 gene fusions have already been identified in human cancers, and it is estimated that up to 80% of solid tumors could benefit from g...
-
Tuesday, June 22, 2021 · 11:00 AM EDTHereditary cancer syndromes are a set of complex diseases, often presenting with diverse clinical phenotypes involving multiple genes of interest with variable penetrance. Large-scale genomic sequencing of multi-gene panels has become the standard...
Rare and Inherited Diseases
-
On-demandAt SOPHiA GENETICS, we collaborate with genetic experts to develop specialized next-generation sequencing (NGS) applications that seamlessly integrate into any laboratory workflow. Today, our partners share how the analytical technology and dedica...
-
On-demandPessoas reais, impactos reais. Assista a uma apresentação imperdível sobre como SOPHiA DDM™ otimiza a análise de exomas e painéis direcionados, inclusive no caso de doenças pediátricas raras. A apresentação será feita pela nossa cliente, Dra. Oliv...
-
On-demandOver the past decade, next-generation sequencing (NGS) has emerged as a comprehensive and cost-effective tool for the diagnosis and research of rare diseases. It is well known that mutations in nuclear DNA can cause a range of human diseases, with...
-
On-demandCe webinar illustre l'apport complémentaire du séquençage moléculaire dans le cas d’un enfant de 15 ans, présentant une agénésie dentaire associée à des anomalies génitales.
Initialement un diagnostic d'oligodonties est suspecté. L'identification... -
On-demandThis corporate satellite was presented live at ESHG 2021 on August 28th, 2021.
Next-Generation Sequencing (NGS) is rapidly improving research efforts for rare and inherited diseases. The adoption of exome sequencing helps determine the variations... -
On-demandOver the last decade, whole-exome sequencing has emerged as a comprehensive and cost-effective tool for researching rare disease-causing variants, including copy number variants (CNVs). As a result, researchers can gain extensive, valuable informa...
-
On-demandLas variaciones en el número de copias (CNV) del ADN son una causa bien documentada de enfermedad genética humana. La detección de CNV es un reto ya que las soluciones analíticas deben alcanzar una resolución a nivel de exón para ofrecer resultado...
-
On-demandThis scientific evidence-webinar will discuss Genotypos Science Labs’ experience with a whole exome sequencing solution, supporting the detection of copy number variants for the management of a complex cases. DNA copy number variations (CNVs) are ...
-
On-demandDNA copy number variations (CNVs) are a well-documented cause of human genetic disease. The detection of CNVs is challenging because analytical solutions must offer exon-level resolution for accurate results.
Whole exome sequencing (WES) is inc... -
Thursday, September 17, 2020 · 5:00 PM CESTA major challenge in the era of precision medicine is to ensure quick and reliable identification of potentially disease-causing genetic variants with a streamlined workflow.
This webinar will focus on how SOPHiA GENETICS overcomes these challe...
Genomics
-
On-demandAt SOPHiA GENETICS, we collaborate with genetic experts to develop specialized next-generation sequencing (NGS) applications that seamlessly integrate into any laboratory workflow. Today, our partners share how the analytical technology and dedica...
-
On-demandA central focus of the BRIDGES project was to establish the validity and utility of personalized risk-based breast cancer prevention, and specifically of gene panel testing, within the clinical routine of high-risk Family Cancer Centers.
To this... -
Tuesday, September 28, 2021 · 11:00 AM EDTIn this webinar, you will discover how the adoption of the SOPHiA DDM™ Platform in combination with Microsoft Azure enables accurate analysis of complex genomics data and reduces the burden of building and maintaining IT infrastructures. This comb...
-
Wednesday, September 15, 2021 · 11:00 AM EDTThe SOPHiA DDM™ Platform enables real-time SARS-CoV-2 surveillance, allowing the detection of new and emerging strains with high accuracy and confidence. Furthermore, as vaccination efforts improve around the globe, the use of SOPHiA DDM™ provides...
-
On-demandSOPHiA GENETICS has demonstrated a proof of concept for real time global variant surveillance of spike protein mutations through the SOPHiA GENETICS' secured peer-network and compared findings to the GISAID timeline. Paragon Genomics SARS-CoV-2 pa... -
On-demandDisclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GEN... -
On-demandOur Co-Founder Lars Steinmetz speaks at Precision Medicine World Conference (PMWC) Virtual COVID-19 Edition on how using precision health data can bring surface insights and create value for different industry players – pharma, diagnostic companie...
BioPharma
-
On-demandThe potential of combining genomics with other health data modalities is massive. However, this influx of information presents a unique set of challenges that we are only beginning to tackle.
Over the past decade, we have witnessed a healthcare r... -
On-demandOver the last 20 years, targeted compounds have been proven effective for non-small cell lung cancer (NSCLC patients), but recent scientific breakthroughs have made immunotherapies a new pillar of cancer care. These recent advances, coupled with t...
-
On-demandPrecision oncology benefits from a wide array of data modalities, including genomics, clinical information, imaging data, pathological findings, and real-world evidence. Integrating and analyzing these diverse datasets enables a holistic understan...
-
On-demandJoin us on a journey to revolutionize clinical research programs with decentralized collective intelligence. See decentralization in motion with the SOPHiA DDM™ Platform, designed to connect and integrate multimodal data from 750+ institutions acr...
-
On-demandThis panel discussion took place at BioData World Congress in Basel, Switzerland on 09 November.
Data integration and AI/ML are seemingly everywhere and are increasingly recognized as critical to accelerating the advancement of precision medicine...
